LL-341070, a new drug candidate, shows promise in repairing vision loss and neurological damage in multiple sclerosis, according to University of Colorado researchers. Published in Nature Communications, the study reveals its ability to enhance myelin repair, restoring vision and brain function in mice. Further testing aims to refine its potential as a breakthrough therapy.